Per oral endoscopic myotomy (POEM) in pediatric patients with esophageal achalasia: First Latin-American experience
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Jul 2020 · 1 min read
In brief
In brief
This retrospective study reports the first Latin American experience with POEM for pediatric esophageal achalasia in five Chilean patients aged 5-15 years. All patients achieved complete dysphagia resolution with significant Eckardt score improvement and no major complications, supporting POEM as a safe alternative to laparoscopic Heller myotomy in children.
Written by the GCMD Library team from the article.
Abstract
Background
Achalasia is the most common primary motor disorder of the esophagus, but its incidence in pediatric patients is low. Laparoscopic Heller myotomy (LHM) is the current surgical standard of care treatment. Per-oral endoscopic myotomy (POEM) has emerged as a safe and effective therapeutic alternative in adult patients. We herein report the outcomes of a cohort of pediatric patients with achalasia treated by POEM at a Chilean medical center.
Methods
This is a retrospective analysis of prospectively collected data on children who underwent POEM for esophageal achalasia. Clinical follow-up was evaluated by recording the Eckardt score, a high-resolution esophageal manometry (HREM) three months after the procedure, and an annual upper gastrointestinal endoscopy.
Results
Five patients with esophageal achalasia confirmed by HREM and with a mean age of 11 (5 to 15) years underwent POEM between 2017 and 2019. One patient had a previous LHM. No morbidity or mortality was observed. All patients resolved their dysphagia and no patient required further interventions. Mean Eckardt score reduced from 10 points preoperatively to 1 point postoperatively.
Two patients currently have mild esophagitis (confirmed by endoscopy).
Conclusion
Our results support the previously reported safety and effectiveness of POEM. Longer follow-up and larger cohorts will be important to confirm its role in the treatment of children with esophageal achalasia.
Type of study
Treatment study.
Level of evidence
Level IV.